Cite
Poole A, Gill D, Hahn AW, et al. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017;doi: 10.1016/j.clgc.2017.08.017.
Poole, A., Gill, D., Hahn, A. W., Johnson, E., Carroll, E., Boucher, K., Nussenzveig, R., Maughan, B., & Agarwal, N. (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical genitourinary cancer, . https://doi.org/10.1016/j.clgc.2017.08.017
Poole, Austin, et al. "Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer." Clinical genitourinary cancer vol. (2017). doi: https://doi.org/10.1016/j.clgc.2017.08.017
Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Sep 06; doi: 10.1016/j.clgc.2017.08.017. Epub 2017 Sep 06. PMID: 28958675.
Copy
Download .nbib